INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.6 USD | +8.56% |
|
+6.51% | -8.27% |
| 13/05 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
| 13/05 | Equities Close Mixed as Markets Parse Consumer Inflation Survey | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 408.4Cr 34TCr | Sales 2025 * | 451.74Cr 38TCr | Capitalization | 1.29TCr 1,08000Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 76Cr 6.34TCr | Net income 2025 * | 96Cr 8.04TCr | EV / Sales 2024 * | 2.14 x |
| Net cash position 2024 * | 418.75Cr 35TCr | Net cash position 2025 * | 540.53Cr 45TCr | EV / Sales 2025 * | 1.67 x |
| P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
14.3
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | +8.56% | ||
| 1 week | +6.51% | ||
| Current month | +10.66% | ||
| 1 month | +6.96% | ||
| 3 months | -2.93% | ||
| 6 months | +8.43% | ||
| Current year | -8.27% |
1 week
52.81
58.93
1 month
50.3558.93
Current year
50.3567.37
1 year
50.2767.37
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 13/14/13 |
| Director of Finance/CFO | 53 | 11/19/11 | |
Pablo Cagnoni
PSD | President | 60 | 05/23/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 01/01/01 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 16/19/16 |
| Director/Board Member | 70 | 20/15/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 254 M€ | +11.45% | - | |
| 2.94% | 1 M€ | -2.17% | - | |
| 2.88% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 57.6 | +8.56% | 7,237,381 |
| 10/24/10 | 53.06 | -0.82% | 1,505,329 |
| 09/24/09 | 53.5 | -0.02% | 1,428,455 |
| 08/24/08 | 53.51 | -1.58% | 2,208,629 |
| 07/24/07 | 54.37 | +0.54% | 1,901,286 |
Delayed Quote Nasdaq, May 14, 2024 at 01:30 am IST
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
15/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.6
USD
Average target price
73.35
USD
Spread / Average Target
+27.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.27% | 1.29TCr | |
| -2.47% | 8.94TCr | |
| +2.76% | 4.07TCr | |
| -12.92% | 3.28TCr | |
| +54.06% | 2.5TCr | |
| -16.51% | 1.53TCr | |
| -42.60% | 1.16TCr | |
| -12.82% | 1.15TCr | |
| +2.85% | 898.19Cr | |
| -7.49% | 822.67Cr |
- Stock Market
- Equities
- INCY Stock
